Gan & Lee Pharmaceuticals

As we bid farewell to 2023, we're proud to look back on a year of results and advancements we made in diabetes treatment. Thank you to our dedicated team for their tireless efforts. Here's to a healthier and brighter 2024! 🎉

🌲 On this special day, may the spirit of Christmas bring you peace, the gladness of Christmas give you hope, and the warmth of Christmas grant you love. Merry Christmas from Gan & Lee! 🌠

We are pleased to announce the initiation and completion of the first patient dosing in the Phase II clinical trial of its innovative Class 1 drug, GZR101 injection. The study is a multi-center Phase II clinical trial comparing the efficacy, safety, and tolerability of GZR101 injection with Insulin Degludec (Tresiba®) in patients with T2DM who are poorly controlled on OAD (Part A) or basal/premixed insulin (Part B). Read more: https://buff.ly/4akXJaV

Gan & Lee Pharmaceutical’s Dual Insulin Analog GZR101 Completes First Dosing in Phase II Clinical Trial-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

🌐 We're excited to announce the debut of Phase III Clinical Evidence for Rapilin™30 in China at IDF 2023! The study results have revealed that in patients with type 1 or type 2 diabetes, Gan & Lee’s Insulin Aspart 30 Injection (Rapilin™30) is similar in efficacy to NovoMix®30, and it indicates that Rapilin™30 shares comparable safety and tolerability with NovoMix®30. Read more: https://buff.ly/3RBtkOd

IDF 2023丨Debut of the Phase III Clinical Evidence in China for Rapilin30-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

We are excited to announce the successful participation of Gan & Lee at the 20th Annual Meeting of Chinese Society of Endocrinology, which took place in Qingdao on December 6-9. At the Gan & Lee booth, we featured the latest diabetes treatment solutions, engaged with the Chinese medical community, and explored industry trends with diabetes practitioners. Additionally, we conducted a satellite symposia to facilitate academic exchange and share insights on diabetes. 🔬💡

🎉 Great News! 🌟Recently, Gan & Lee announced NMPA IND clearance for Oral GLP-1 Receptor Agonist (GZR18 Tablet). Read more:
-1

Gan & Lee Pharmaceuticals Announces IND Clearance by the NMPA for the Oral GLP-1 Receptor Agonist (GZR18 Tablet)-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

🎉 Great News! 🌟Recently, Gan & Lee announced NMPA IND clearance for Oral GLP-1 Receptor Agonist (GZR18 Tablet). Read more: https://buff.ly/3Rp9ea3
-1

Gan & Lee Pharmaceuticals Announces IND Clearance by the NMPA for the Oral GLP-1 Receptor Agonist (GZR18 Tablet)-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Good News！🌟 Recently, Gan & Lee Pharmaceuticals' insulin aspart 30 phase III clinical study results were selected for IDF 2023. Read more: 🌐 ✨

Highlights Preview! Gan & Lee Pharmaceuticals' Insulin Aspart 30 Phase III Clinical Study Results Selected for IDF 2023-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

We are pleased to share Gan & Lee’s successful present at the 25th Scientific Meeting of the Chinese Diabetes Society held in Wuhan on November 22-25. At the Gan & Lee booth, we showcased diabetes treatment solutions, listened to the voices of the Chinese medical community, and discussed the industry trends with practitioners in the field of diabetes. We also held a satellite symposia under the theme "Excellence Stands Out: Overcoming the Challenges of Glucose Control". Professor Ling Gao from Renmin Hospital of Wuhan University was invited to deliver an impressive lecture. It was an unforgettable opportunity for academic exchange and insight sharing focused on diabetes! 🔬💡

🎉 Great News! 🌏 We are happy to announce our recent achievement - Customs AEO Certification! 🏆 This prestigious recognition not only makes us a customs "VIP" but also underscores our commitment to international standards in supply chain management and compliance. Read more: https://www.ganlee.com/detail/729.html🌐✨

Gan & Lee - Dedicated to Improving Human Health Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

November is Diabetes Awareness Month, and at Gan & Lee, we're dedicated to raising awareness and supporting patients worldwide. Join us for World Diabetes Day in spreading the word and sharing stories of hope and resilience. 💙 Together, we can inspire change.

We would like to share the exciting highlights from our Fun Sports held last Thursday! 🎉 To promote diabetes awareness month, we held a variety of games and activities like iceless curling, archery, bean bag toss, pitch-pot, etc. It was a day filled with enthusiasm, camaraderie, and joy! 💪💙🎁 Congratulations to all the game winners! 🙌 Thank you for being part of this memorable day! 💙

🏀Dribbling towards a healthier tomorrow! Our basketball game isn't just for fun – it's about raising diabetes awareness, inspiring healthy choices, and fostering community spirit. Come, shoot, score, and join the cause! 🌟

Recently, Gan & Lee Pharmaceuticals announced the 2023 third-quarter report with financial results, product highlights, and corporate updates. Read more:

www.ganlee.com.cn

Good news! 🌟 Gan & Lee is pleased to announce that we have won the Kazakh government tender for insulin aspart injection (Rapilin™) and insulin pen (GanleePen™) products. Read more:

Gan & Lee Pharmaceuticals Won the Kazakh Government Tender for Insulin Aspart and Insulin Pen-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Good news! Recently, Gan & Lee published the results of the Phase I clinical trial of three insulin products – Basalin® (insulin glargine), Prandilin® (insulin lispro), and Rapilin® (insulin aspart) - in the peer-reviewed journal Diabetes, Obesity and Metabolism. Read more:

Gan & Lee Pharmaceuticals' Overseas Clinical Research on Three Insulin Products was Published in Journal Diabetes, Obesity and Metabolism-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Gan & Lee presented data from two overseas Phase III clinical studies of Basalin® in a short oral discussion on October 5 at . The results of the studies showed that Basalin® is bioequivalent to Lantus® in terms of immunogenicity, efficacy, and safety. The study adds further strong evidence to support the efficacy and safety of Basalin® for the treatment of diabetes. Read more: https://www.ganlee.com/detail/721.html

Great news! We are pleased to announce that Gan & Lee has submitted the MAA for the biosimilar insulin lispro to the EMA and has recently received the positive validation letter from the EMA, entering the review phase. Read more:

The Scientific Evaluation from EMA on Marketing Authorisation Application of Gan & Lee Insulin Lispro biosimilar Starts upon the Positive Validation Letter-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Great news! We are pleased to announce that Gan & Lee has submitted the MAA for the biosimilar insulin aspart to the EMA and has recently received the positive validation letter from the EMA, entering the review phase. Read more:

The Scientific Evaluation from EMA on the Marketing Authorisation Application of Gan & Lee Insulin Aspart biosimilar starts upon the Positive Validation Letter-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Happy National Day of China! 🎉 On this special occasion, we wish everyone good health and happiness. As we celebrate together, let's remember the importance of taking care of our well-being, especially for those managing diabetes. Stay safe and enjoy the festivities responsibly! ❤️🏮

🌕 Wishing you a luminous and joyous Mid-Autumn Festival! May the glow of the full moon bring warmth to your heart and your loved ones. Remember to take care of your diabetes while savoring the festivities.

The 59th EASD Annual Meeting is less than one week away! We are pleased to share that our abstracts for two Phase III clinical trials on Gan & Lee insulin glargine has been accepted by EASD. Dr. Elena A Christofides, the leading Principal Investigator of two studies, will give two short oral presentations during the congress. The poster of the selected abstracts will also be exhibited onsite. Make sure not to miss out and register through: https://www.easd.org.

Gan & Lee is pleased to announce the launch of our 2023 Talent Development Program. Our program consists of five projects, each of which is tailored for the graduates and people in different management positions. The projects include a series of training courses such as leadership, communication skills, product knowledge, corporate culture, etc. At Gan & Lee, we're committed to nurturing talents and empowering our employees to achieve their full potential. To learn more about us, please visit: www.ganlee.com.🚀 "

Recently, Gan & Lee announced that the first subject was successfully dosed in the Phase II clinical trial of GZR4 in China. Read more:

Gan & Lee Pharmaceutical’s Once-Weekly Insulin GZR4 Completes First Dosing in Phase II Clinical Trial-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Recently Gan & Lee Pharmaceuticals announced the 2023 semi-annual report with financial results, product highlights, and corporate updates. Read more�https://www.ganlee.com/uploads/files/2023/0825/qPSWvL0cRiZuaFrBUNqBiuoLVbSGhK80VuzmDH8q.pdf

Great news! We are pleased to announce that the EMA has accepted the MAA that Gan & Lee Pharmaceuticals Europe GmbH has submitted for the proposed biosimilar insulin glargine injection, and the application enters into the formal review stage. Read more:

The Scientific Evaluation from EMA on Marketing Authorisation Application of Gan & Lee Insulin Glargine biosimilar starts upon the Positive Validation Letter-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Recently, Gan & Lee's GLP-1 RA (GZR18) has completed the first subject dosing for two Phase IIb clinical trials in China. These trials are aimed at evaluating the efficacy and safety of GZR18 in adult patients with type 2 diabetes and in patients with obese/overweight. Read more：

Gan & Lee Pharmaceuticals GZR18 Completes First Dosing in Two Phase IIb Clinical Trials-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

Gan & Lee is pleased to announce that China's NMPA has cleared Gan & Lee's IND application for GLR1023 Injection. As a proposed biosimilar to Secukinumab (COSENTYX), GLR1023 is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

NMPA Issued IND Clearance for Gan & Lee’s First Monoclonal Antibody GLR1023 Injection-Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company...

🎉 What an exhilarating experience! Gan & Lee's BD team had the privilege of actively participating in the diabetes workshop at Siriraj Hospital, Bangkok's Top 1 public hospital. Joined by our incredible partners, BJC COSMA, we united to promote our insulin glargine product, Gansulog®, as a warm-up for the upcoming new product conference, bringing a remarkable impact to diabetes care and empowering lives! 💙

🎉 Join us today at American Diabetes Association's 83rd Scientific Sessions in San Diego! Discover more about Gan & Lee at Booth 1915. Connect with experts, explore advancements, and be part of the diabetes community. We are here waiting for you!